Psoriasis and Ayurvedic Treatment by Prof Dr Murali Manohar Chirumamilla M.D. (Ayurveda) For Details, please visit : E mail : email@example.com In-depth health education videos in Telugu about various disea. Ayurvedic Treatment For Psor…
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials Program, OPT Pivotal #1 and OPT Pivotal #2 , evaluating the efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
Pfizer's ( PFE ) Janus kinase inhibitor XELJANZ (tobacitinib), a twice-daily oral pill for the treatment of moderate-to-severe plaque psoriasis, meets its primary endpoints in two Phase 3 clinical trials, OPT#1 and OPT#2. The primary efficacy endpoints were a statistically significant superiority over placebo at week 16 in the proportion of patients achieving a Physicians Global Assessment …
By Dow Jones Business News, April 22, 2014, 08:53:00 AM EDT
By Tess Stynes
Pfizer Inc. ( PFE ) said two Phase 3 studies to evaluate the effectiveness and safety of its treatment for adults with moderate-to-severe plaque psoriasis showed positive results.
The studies of the twice-daily pill–known as tofacitinib — at two dosing levels was more effective than a placebo in achieving a response of “clear” or “almost clear” at 16 weeks and in the portion of patients achieving at least a 75% reduction in the severity and area affected by psoriasis.
Pfizer plans to submit a supplemental new drug application to the U.S. Food and Drug Administration by early next year.
Tofacitinib — sold domestically under the brand name Xeljanz — is approved in more than 20 countries for adults with hard-to-treat cases of moderate-to-severe rheumatoid arthritis.
Write to Tess Stynes at firstname.lastname@example.org
Subscribe to WSJ: http://online.wsj.com?mod=djnwires